Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer
Shots:
- The first patient has been dosed in a head-to-head P-III trial of ivonescimab evaluating the clinical efficacy and safety of ivonescimab vs tislelizumab in combination with CT as 1L treatment of LA or metastatic sq-NSCLC
- Additionally, 4 P-III trials have been initiated globally incl. 3 head-to-head trials i.e., P-III study of ivonescimab monotx. as a 1L treatment for NSCLC; international P-III study of Ivonescimab + CT for EGFR-mutated, LA or metastatic non-sq. NSCLC; ivonescimab + CT for advanced sq. NSCLC and international P-III study of ivonescimab + CT as 1L treatment for metastatic sq. NSCLC
- Ivonescimab, a PD-1/VEGF bi-specific Ab which was currently developed by Akeso in China, Australia
Ref: PRNewswire | Image: Akeso
Related News:- Akeso's Ivonescimab Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Non-Small-Cell Lung Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
